Bhatti Sadia, Asim Sadaf Ahmed, Sajid Madiha, Iqbal Tayyaba, Shaikh Fozia, Waseem Hira Fatima
Dow International Medical College, Karachi, Pakistan.
Department of Dermatology, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan.
J Pak Med Assoc. 2025 Jul;75(7):1082-1085. doi: 10.47391/JPMA.20767.
To compare the efficacy of intralesional triamcinolone acetonide alone and in combination with 5 -fluorouracil in the management of keloids.
The prospective cross-sectional study was conducted at the Dermatology outpatient department, Ojha campus, Dow University of Health Sciences, Karachi, from April to September 2023, and comprised patients with keloids who were divided into group A receiving intralesional triamcinolone acetonide 40mg/ml alone, and group B receiving a combination of triamcinolone acetonide 40mg/ml and 5-fluorouracil 50mg/ml. The medication was given monthly for 6 months, and efficacy was assessed using the Vancouver Scar Scale on each visit before the injection. Data was analysed with SPSS version 26.
Of the 66 patients, 33(50%) were in group A; 19(57.6%) females and 14(42.4%) males with mean age 34.39±9.81 years. There were 33(50%) patients in group B; 20(60.6%) females and 13(39.4%) males with mean age 33.75±11.51 years. In group B, good to excellent response was seen in 31 (95%) cases compared to 23 (70%) in group A. Side effects such as atrophy (3 cases, 9.1%) and telangiectasia (2 cases, 6.1%) were more prevalent in Group A compared to atrophy (1 case, 3%) and telangiectasia (1 case, 3%) in Group B.
Intralesional triamcinolone acetonide in combination with 5-fluorouracil was found to be more effective with faster response and less side-effects compared to triamcinolone acetonide alone.
比较曲安奈德皮损内注射单独使用及联合5-氟尿嘧啶治疗瘢痕疙瘩的疗效。
2023年4月至9月,在卡拉奇道健康科学大学奥贾校区皮肤科门诊进行了一项前瞻性横断面研究,研究对象为瘢痕疙瘩患者,分为A组(单独接受40mg/ml曲安奈德皮损内注射)和B组(接受40mg/ml曲安奈德与50mg/ml 5-氟尿嘧啶联合治疗)。每月给药1次,共6个月,每次注射前使用温哥华瘢痕量表评估疗效。采用SPSS 26版软件进行数据分析。
66例患者中,A组33例(50%);女性19例(57.6%),男性14例(42.4%),平均年龄34.39±9.81岁。B组33例(50%);女性20例(60.6%),男性13例(39.4%),平均年龄33.75±11.51岁。B组31例(95%)患者反应良好至极佳,而A组为23例(70%)。A组萎缩(3例,9.1%)和毛细血管扩张(2例,6.1%)等副作用比B组的萎缩(1例,3%)和毛细血管扩张(1例,3%)更常见。
与单独使用曲安奈德相比,曲安奈德皮损内注射联合5-氟尿嘧啶疗效更佳,起效更快,副作用更少。